{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:19:17Z","timestamp":1791951557708,"version":"4.3.4"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR202206080014"],"award-info":[{"award-number":["ZR202206080014"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.phrs.2025.107915","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:53:59Z","timestamp":1755503639000},"page":"107915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Precision targeting of androgen receptor\u2013ferroptosis crosstalk in prostate cancer: From mechanisms to therapeutic strategies"],"prefix":"10.1016","volume":"219","author":[{"given":"Dongfang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-457X","authenticated-orcid":false,"given":"Denglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib1","first-page":"229","article-title":"2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10437","key":"10.1016\/j.phrs.2025.107915_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41419-025-07559-3","article-title":"BCAT2 binding to PCBP1 regulates the PI3K\/AKT signaling pathway to inhibit autophagy-related apoptosis and ferroptosis in prostate cancer","volume":"16","author":"Mei","year":"2025","journal-title":"Cell death Dis."},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"Cornford, EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2025.107915_bib5","article-title":"Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: implications for precision Medicine","volume":"185","author":"Wang","year":"2025","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ajpath.2023.12.003","article-title":"Androgen receptor-interacting proteins in prostate cancer development and therapy resistance","volume":"194","author":"Culig","year":"2024","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2025.107915_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114794","article-title":"Androgen receptor phosphorylated at Ser815: the expression and function in the prostate and tumor-derived cells","volume":"194","author":"Yokobori","year":"2021","journal-title":"Biochem Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib8","first-page":"271","article-title":"Androgen receptor defects: historical, clinical, and molecular perspectives","volume":"16","author":"Quigley","year":"1995","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2025.107915_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"Androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu Rev. Pharm. Toxicol."},{"issue":"26","key":"10.1016\/j.phrs.2025.107915_bib10","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7604","key":"10.1016\/j.phrs.2025.107915_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature17954","article-title":"Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"issue":"5928","key":"10.1016\/j.phrs.2025.107915_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107915_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.phrs.2025.107915_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/procel\/pwae003","article-title":"Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond","volume":"15","author":"Mao","year":"2024","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell death Dis."},{"issue":"13","key":"10.1016\/j.phrs.2025.107915_bib17","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","article-title":"Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones","volume":"186","author":"Liang","year":"2023","journal-title":"Cell"},{"issue":"7915","key":"10.1016\/j.phrs.2025.107915_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in t cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.phrs.2025.107915_bib19","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/1078-0432.CCR-20-3182","article-title":"Iron induces cell death and strengthens the efficacy of antiandrogen therapy in prostate cancer models","volume":"26","author":"Bordini","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.phrs.2025.107915_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.phrs.2025.107915_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1084\/jem.70.6.543","article-title":"Quantitative studies of prostatic secretion: I. Characteristics of the normal secretion; the influence of thyroid, suprarenal, and testis extirpation and androgen substitution on the prostatic output","volume":"70","author":"Huggins","year":"1939","journal-title":"J. Exp. Med"},{"issue":"6","key":"10.1016\/j.phrs.2025.107915_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.72.6.747","article-title":"Quantitative studies of prostatic secretion: ii. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs","volume":"72","author":"Huggins","year":"1940","journal-title":"J. Exp. Med"},{"issue":"8","key":"10.1016\/j.phrs.2025.107915_bib23","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0021-9258(18)93542-8","article-title":"The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro","volume":"243","author":"Bruchovsky","year":"1968","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/joe.0.0450531","article-title":"A soluble androgen receptor in the cytoplasm of rat prostate","volume":"45","author":"Mainwaring","year":"1969","journal-title":"J. Endocrinol."},{"issue":"4850","key":"10.1016\/j.phrs.2025.107915_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/science.3353727","article-title":"Cloning of human androgen receptor complementary DNA and localization to the x chromosome","volume":"240","author":"Lubahn","year":"1988","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.phrs.2025.107915_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/pros.23360","article-title":"Discovery of LHRH and development of LHRH analogs for prostate cancer treatment","volume":"77","author":"Schally","year":"2017","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.phrs.2025.107915_bib27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2025.107915_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"C.-A.-. Investigators, abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"9724","key":"10.1016\/j.phrs.2025.107915_bib29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Cancer Foundation\/Department of defense prostate cancer clinical trials, antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2025.107915_bib30","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"A. Investigators, increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"28","key":"10.1016\/j.phrs.2025.107915_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201859","article-title":"De novo design of an androgen receptor DNA binding Domain-Targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","article-title":"Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"6-8","key":"10.1016\/j.phrs.2025.107915_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/bj0030313","volume":"3","author":"Moore","year":"1908","journal-title":"Biochem J."},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib35","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/0006-291X(77)90623-4","article-title":"Effect of antioxidants on cultured human diploid fibroblasts exposed to cystine-free medium","volume":"74","author":"Bannai","year":"1977","journal-title":"Biochem Biophys. Res Commun."},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0005-2760(82)90150-3","article-title":"Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides","volume":"710","author":"Ursini","year":"1982","journal-title":"Biochim Biophys. Acta"},{"issue":"6","key":"10.1016\/j.phrs.2025.107915_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/0896-6273(89)90043-3","article-title":"Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress","volume":"2","author":"Murphy","year":"1989","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.phrs.2025.107915_bib38","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1073\/pnas.89.17.8264","article-title":"Growth factors and vitamin e modify neuronal glutamate toxicity","volume":"89","author":"Schubert","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1535-6108(03)00050-3","article-title":"Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells","volume":"3","author":"Dolma","year":"2003","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","article-title":"Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells","volume":"15","author":"Yang","year":"2008","journal-title":"Chem. Biol."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.107915_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib42","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"7545","key":"10.1016\/j.phrs.2025.107915_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"34","key":"10.1016\/j.phrs.2025.107915_bib45","doi-asserted-by":"crossref","first-page":"E4966","DOI":"10.1073\/pnas.1603244113","article-title":"Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","article-title":"Selenium utilization by GPX4 is required to prevent Hydroperoxide-Induced ferroptosis","volume":"172","author":"Ingold","year":"2018","journal-title":"Cell"},{"issue":"7784","key":"10.1016\/j.phrs.2025.107915_bib47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"issue":"7860","key":"10.1016\/j.phrs.2025.107915_bib48","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","article-title":"GTP cyclohydrolase 1\/Tetrahydrobiopterin counteract ferroptosis through lipid remodeling","volume":"6","author":"Kraft","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib50","article-title":"Basics of androgen synthesis and action","volume":"36","author":"Naamneh Elzenaty","year":"2022","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2025.107915_bib51","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1021\/acs.jmedchem.3c00442","article-title":"Non-steroidal CYP17A1 inhibitors: discovery and assessment","volume":"66","author":"Wrobel","year":"2023","journal-title":"J. Med Chem."},{"issue":"14","key":"10.1016\/j.phrs.2025.107915_bib52","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1021\/bi00517a014","article-title":"Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17 alpha-hydroxylase and c17,20-lyase) associated with one protein","volume":"20","author":"Nakajin","year":"1981","journal-title":"Biochemistry"},{"issue":"4170","key":"10.1016\/j.phrs.2025.107915_bib53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","article-title":"Steroid 5alpha-reductase deficiency in man: an inherited form of Male pseudohermaphroditism","volume":"186","author":"Imperato-McGinley","year":"1974","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/CCO.0000000000001032","article-title":"Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology","volume":"36","author":"Kango","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharm. Sin."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2004.12.037","article-title":"Molecular chaperones throughout the life cycle of the androgen receptor","volume":"231","author":"Prescott","year":"2006","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.phrs.2025.107915_bib57","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1093\/nar\/gkaa178","article-title":"Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element","volume":"48","author":"Kregel","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.phrs.2025.107915_bib58","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1158\/0008-5472.CAN-19-3447","article-title":"Shaping chromatin states in prostate cancer by pioneer transcription factors","volume":"80","author":"Hankey","year":"2020","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s10147-019-01412-2","article-title":"Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer","volume":"24","author":"Miyake","year":"2019","journal-title":"Int J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing Castration-resistant prostate Cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.7150\/thno.49384","article-title":"ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib64","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1373\/clinchem.2017.281295","article-title":"In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in circulating tumor cells","volume":"64","author":"El-Heliebi","year":"2018","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14728222.2018.1439016","article-title":"The potential of AR-V7 as a therapeutic target","volume":"22","author":"Uo","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107915_bib67","doi-asserted-by":"crossref","first-page":"1083486","DOI":"10.3389\/fcell.2023.1083486","article-title":"The epigenetic function of androgen receptor in prostate cancer progression","volume":"11","author":"Sawada","year":"2023","journal-title":"Front Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib68","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-022-32701-6","article-title":"Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity","volume":"13","author":"Westbrook","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107915_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217286","article-title":"Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC","volume":"605","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2025.107915_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107234","article-title":"PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer","volume":"205","author":"Zhang","year":"2024","journal-title":"Pharm. Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055014","article-title":"Role of ganetespib, an HSP90 inhibitor, in cancer therapy: from molecular mechanisms to clinical practice","volume":"24","author":"Youssef","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.phrs.2025.107915_bib73","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1158\/1078-0432.CCR-18-3212","article-title":"Pharmacodynamic and clinical results from a phase I\/II study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer","volume":"25","author":"Slovin","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8641","article-title":"PI5P4Kalpha supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition","volume":"9","author":"Triscott","year":"2023","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib75","article-title":"Characterization of the peroxisomal proteome and redox balance in human prostate cancer cell lines","volume":"13","author":"Hussein","year":"2024","journal-title":"Antioxid. (Basel)"},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib76","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.devcel.2025.02.004","article-title":"Mechanisms of ferroptosis sensitization and resistance","volume":"60","author":"Lee","year":"2025","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","article-title":"Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects","volume":"9","author":"Ru","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"21","key":"10.1016\/j.phrs.2025.107915_bib78","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1073\/pnas.0801318105","article-title":"Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle","volume":"105","author":"Sendamarai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib79","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.tem.2021.04.010","article-title":"Ferritinophagy and ferroptosis in the management of metabolic diseases","volume":"32","author":"Ajoolabady","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.107915_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2018.09.022","article-title":"Iron and redox cycling. Do's and Don'ts","volume":"133","author":"Koppenol","year":"2019","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.phrs.2025.107915_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.586578","article-title":"Oxidative damage and antioxidant defense in ferroptosis","volume":"8","author":"Kuang","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2025.107915_bib82","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06328","article-title":"Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport","volume":"4","author":"Hashidate-Yoshida","year":"2015","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nchembio.2238","article-title":"Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis","volume":"13","author":"Kagan","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.chembiol.2018.11.016","article-title":"Exogenous monounsaturated fatty acids promote a Ferroptosis-Resistant cell state","volume":"26","author":"Magtanong","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib85","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1038\/s41467-021-27414-1","article-title":"Molecular basis for redox control by the human cystine\/glutamate antiporter system xc","volume":"12","author":"Parker","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib86","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cmet.2008.07.005","article-title":"Glutathione peroxidase 4 senses and translates oxidative stress into 12\/15-lipoxygenase dependent- and AIF-mediated cell death","volume":"8","author":"Seiler","year":"2008","journal-title":"Cell Metab."},{"issue":"7784","key":"10.1016\/j.phrs.2025.107915_bib87","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"issue":"7924","key":"10.1016\/j.phrs.2025.107915_bib88","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05022-3","article-title":"A non-canonical vitamin k cycle is a potent ferroptosis suppressor","volume":"608","author":"Mishima","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.phrs.2025.107915_bib89","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41589-020-0613-y","article-title":"Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers","volume":"16","author":"Soula","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib90","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-024-01599-6","article-title":"METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-025-02170-6","article-title":"Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107915_bib92","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41419-024-06937-7","article-title":"Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators","volume":"15","author":"Feng","year":"2024","journal-title":"Cell death Dis."},{"issue":"14","key":"10.1016\/j.phrs.2025.107915_bib93","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","article-title":"ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis","volume":"84","author":"Shrestha","year":"2024","journal-title":"Cancer Res"},{"issue":"9-10","key":"10.1016\/j.phrs.2025.107915_bib94","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s10495-024-01941-w","article-title":"Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis","volume":"29","author":"Fan","year":"2024","journal-title":"Apoptosis"},{"issue":"19","key":"10.1016\/j.phrs.2025.107915_bib95","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","article-title":"Androgen receptor variants confer castration resistance in prostate cancer by counteracting Antiandrogen-Induced ferroptosis","volume":"83","author":"Sun","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2025.107915_bib96","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54166","article-title":"Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis","volume":"9","author":"Nassar","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib97","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41467-020-16126-7","article-title":"2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer","volume":"11","author":"Blomme","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2025.107915_bib98","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1535-7163.MCT-06-0056","article-title":"Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action","volume":"5","author":"Husbeck","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib99","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2019.03.032","article-title":"Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke","volume":"177","author":"Alim","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib100","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.7976","article-title":"Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration\u2011resistant prostate cancer","volume":"45","author":"Yang","year":"2021","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib101","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3390\/cancers2021354","article-title":"The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells","volume":"2","author":"Schultz","year":"2010","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib102","first-page":"96","article-title":"Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators","volume":"4","author":"Mondal","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"19","key":"10.1016\/j.phrs.2025.107915_bib103","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-08-0591","article-title":"Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer","volume":"14","author":"Sharifi","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115470","article-title":"Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth","volume":"44","author":"Fidelito","year":"2025","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.phrs.2025.107915_bib105","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.7150\/ijbs.101039","article-title":"Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2025.107915_bib106","doi-asserted-by":"crossref","first-page":"1110146","DOI":"10.3389\/fphar.2023.1110146","article-title":"Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR\/GPX4 axis activated ferroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107915_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100985","article-title":"Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells","volume":"70","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib108","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41420-023-01383-4","article-title":"Iron supplementation enhances RSL3-induced ferroptosis to treat naive and prevent castration-resistant prostate cancer","volume":"9","author":"Maccarinelli","year":"2023","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-024-01564-3","article-title":"Ferroptosis: principles and significance in health and disease","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12943-023-01804-z","article-title":"Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1","volume":"22","author":"Jiang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib111","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12967-023-04111-9","article-title":"Protectin conjugates in tissue regeneration 1 alleviates sepsis-induced acute lung injury by inhibiting ferroptosis","volume":"21","author":"Lv","year":"2023","journal-title":"J. Transl. Med"},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib112","article-title":"Oxidative stress and skin diseases: the role of lipid peroxidation","volume":"14","author":"Li Pomi","year":"2025","journal-title":"Antioxid. (Basel)"},{"key":"10.1016\/j.phrs.2025.107915_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103312","article-title":"Plin4 exacerbates cadmium-decreased testosterone level via inducing ferroptosis in testicular leydig cells","volume":"76","author":"Zhang","year":"2024","journal-title":"Redox Biol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib114","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","article-title":"ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation","volume":"10","author":"Park","year":"2019","journal-title":"Cell death Dis."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010449","article-title":"Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis","volume":"24","author":"Rochette","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107915_bib116","article-title":"GPX4, ferroptosis, and diseases","volume":"174","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib117","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10637-021-01070-0","article-title":"System Xc(-): a key regulatory target of ferroptosis in cancer","volume":"39","author":"Liu","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.phrs.2025.107915_bib118","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-0716-0247-8_11","article-title":"Detection of ferroptosis by BODIPY 581\/591 C11","volume":"2108","author":"Martinez","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"34","key":"10.1016\/j.phrs.2025.107915_bib119","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1039\/C4OB00935E","article-title":"A new class of high-contrast Fe(II) selective fluorescent probes based on spirocyclized scaffolds for visualization of intracellular labile iron delivered by transferrin","volume":"12","author":"Niwa","year":"2014","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.chembiol.2021.11.001","article-title":"PALP: a rapid imaging technique for stratifying ferroptosis sensitivity in normal and tumor tissues in situ","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"23","key":"10.1016\/j.phrs.2025.107915_bib121","doi-asserted-by":"crossref","first-page":"8939","DOI":"10.1021\/acs.analchem.3c00864","article-title":"Fluorescent Turn-On probes for visualizing GPx4 levels in live cells and predicting drug sensitivity","volume":"95","author":"Wang","year":"2023","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2025.107915_bib122","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41557-023-01249-3","article-title":"A locally activatable sensor for robust quantification of organellar glutathione","volume":"15","author":"Emmert","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.phrs.2025.107915_bib123","article-title":"Transferrin-based radiolabeled probe predicts the sensitivity of human renal cancer cell lines to ferroptosis inducer erastin","volume":"26","author":"Shibata","year":"2021","journal-title":"Biochem Biophys. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib124","article-title":"Lipid metabolism and ferroptosis","volume":"10","author":"Lee","year":"2021","journal-title":"Biol. (Basel)"},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cell.2024.10.047","article-title":"ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107915_bib126","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1158\/0008-5472.CAN-18-2634","article-title":"Assessment of tumor redox status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic acid PET imaging of system x(c) (-) activity","volume":"79","author":"McCormick","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107915_bib127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12974-018-1080-1","article-title":"[(18)F]FSPG-PET reveals increased cystine\/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis","volume":"15","author":"Hoehne","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"20","key":"10.1016\/j.phrs.2025.107915_bib128","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/1078-0432.CCR-20-0644","article-title":"Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET\/CT imaging in patients with newly diagnosed and recurrent prostate cancer","volume":"26","author":"Park","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2967\/jnumed.120.252460","article-title":"Ferronostics: measuring tumoral ferrous iron with PET to predict sensitivity to Iron-Targeted cancer therapies","volume":"62","author":"Zhao","year":"2021","journal-title":"J. Nucl. Med"},{"issue":"10","key":"10.1016\/j.phrs.2025.107915_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add8539","article-title":"Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac\/kidney injuries","volume":"9","author":"Zeng","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib131","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1021\/acsami.1c17507","article-title":"Efficient magnetic Nanocatalyst-Induced Chemo- and ferroptosis synergistic cancer therapy in combination with T(1)-T(2) Dual-Mode magnetic resonance imaging through doxorubicin delivery","volume":"14","author":"Zhu","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"9","key":"10.1016\/j.phrs.2025.107915_bib132","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1039\/D0NR08757B","article-title":"Iron-based nanoparticles for MR imaging-guided ferroptosis in combination with photodynamic therapy to enhance cancer treatment","volume":"13","author":"Chen","year":"2021","journal-title":"Nanoscale"},{"issue":"8","key":"10.1016\/j.phrs.2025.107915_bib133","first-page":"571","article-title":"Nanotechnology utilizing ferroptosis inducers in cancer treatment, Anti-cancer","volume":"24","author":"Farzipour","year":"2024","journal-title":"Agents Med. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2025.107915_bib134","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting ferroptosis to iron out cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.phrs.2025.107915_bib135","first-page":"613","article-title":"Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: insights and future perspectives","volume":"17","author":"Qiao","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib136","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1021\/acsnano.4c16981","article-title":"Nanovesicles for lipid metabolism Reprogram-Enhanced ferroptosis and magnetotherapy of refractory tumors and inhibiting metastasis with activated innate immunity","volume":"19","author":"Cheng","year":"2025","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.phrs.2025.107915_bib137","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147878","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.phrs.2025.107915_bib138","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.phrs.2025.107915_bib139","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2025.107915_bib140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41585-022-00677-z","article-title":"Experimental in vitro, ex vivo and in vivo models in prostate cancer research","volume":"20","author":"Sailer","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"7664","key":"10.1016\/j.phrs.2025.107915_bib141","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107915_bib142","article-title":"Characteristics and biomarkers of ferroptosis","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107915_bib143","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cpt.2022.10.002","article-title":"Inaugurating a novel adjuvant therapy in urological cancers: ferroptosis","volume":"1","author":"Xie","year":"2023","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107915_bib144","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-23-2796","article-title":"JMJD6 rewires ATF4-dependent glutathione metabolism to confer ferroptosis resistance in SPOP-mutated prostate cancer","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:44:27Z","timestamp":1772880267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":144,"alternative-id":["S1043661825003408"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107915","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting of androgen receptor\u2013ferroptosis crosstalk in prostate cancer: From mechanisms to therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107915"}}